<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04991129</url>
  </required_header>
  <id_info>
    <org_study_id>JJSW-01</org_study_id>
    <nct_id>NCT04991129</nct_id>
  </id_info>
  <brief_title>The Safety and Efficacy of Multiple-dose of WJ01024 in Subject With Advanced Cancer</brief_title>
  <official_title>A Dose Escalation and Dose Expansion Study of WJ01024 to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy for Patients With Advanced Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Suzhou Junjing BioSciences Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Suzhou Junjing BioSciences Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A clinical study of WJ01024 in subjects with advanced cancer in China, to evaluate the&#xD;
      safety, tolerability, PK and efficacy of WJ01024. This study includes a dose escalation part&#xD;
      and a dose expansion part. Patients receive WJ01024 on Day 1 and Day 3 of each week, 4 weeks&#xD;
      as a cycle, until disease progression, or intolerable toxicity , withdrawal of consent, or&#xD;
      end of the study, whichever occurs first.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 10, 2021</start_date>
  <completion_date type="Anticipated">April 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">July 30, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Sequential</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The incidence of adverse events (AE) and serious adverse events (SAE) were assessed</measure>
    <time_frame>2 years</time_frame>
    <description>Incidence and severity of adverse events (AE) and serious adverse events (SAE) as assessed according to NCI-CTCAE 5.0, as well as abnormalities in vital signs, electrocardiogram, and laboratory tests</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ORR</measure>
    <time_frame>2 years</time_frame>
    <description>DLT, MTD, RP2D, Number of participants and severity with treatment-related Adverse events as assessed by CTCAE V5.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DOR</measure>
    <time_frame>2 years</time_frame>
    <description>Duration of Response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DCR</measure>
    <time_frame>2 years</time_frame>
    <description>Disease Control Rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS</measure>
    <time_frame>2 years</time_frame>
    <description>Progression-free survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax</measure>
    <time_frame>2 years</time_frame>
    <description>Maximum Plasma Concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax</measure>
    <time_frame>2 years</time_frame>
    <description>Time to Cmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-t</measure>
    <time_frame>2 years</time_frame>
    <description>Area under the concentration versus time curve from time 0 to the last measurable concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-inf</measure>
    <time_frame>2 years</time_frame>
    <description>AUC from time 0 to infinity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kel</measure>
    <time_frame>2 years</time_frame>
    <description>Elimination rate constant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2</measure>
    <time_frame>2 years</time_frame>
    <description>Elimination half life time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F</measure>
    <time_frame>2 years</time_frame>
    <description>Clearance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vd/F</measure>
    <time_frame>2 years</time_frame>
    <description>Apparent volume of distribution</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rac</measure>
    <time_frame>2 years</time_frame>
    <description>Accumulation factor</description>
  </secondary_outcome>
  <number_of_arms>10</number_of_arms>
  <enrollment type="Anticipated">108</enrollment>
  <condition>Advanced Hematologic Malignancies</condition>
  <condition>Advanced Solid Tumors</condition>
  <arm_group>
    <arm_group_label>WJ01024 5mg repeat dose every 28 days</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>WJ01024 10mg repeat dose every 28 days</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>WJ01024 20mg repeat dose every 28 days</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>WJ01024 40mg repeat dose every 28 days</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>WJ01024 60mg repeat dose every 28 days</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>WJ01024 80mg repeat dose every 28 days</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>WJ01024 100mg repeat dose every 28 days</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>WJ01024 120mg repeat dose every 28 days</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>WJ01024 140mg repeat dose every 28 days</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>WJ01024 160mg repeat dose every 28 days</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>WJ01024</intervention_name>
    <description>5mg: WJ01024, Q4W, twice per week</description>
    <arm_group_label>WJ01024 5mg repeat dose every 28 days</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>WJ01024</intervention_name>
    <description>10mg: WJ01024, Q4W, twice per week</description>
    <arm_group_label>WJ01024 10mg repeat dose every 28 days</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>WJ01024</intervention_name>
    <description>20mg: WJ01024, Q4W, twice per week</description>
    <arm_group_label>WJ01024 20mg repeat dose every 28 days</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>WJ01024</intervention_name>
    <description>40mg: WJ01024, Q4W, twice per week</description>
    <arm_group_label>WJ01024 40mg repeat dose every 28 days</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>WJ01024</intervention_name>
    <description>60mg: WJ01024, Q4W, twice per week</description>
    <arm_group_label>WJ01024 60mg repeat dose every 28 days</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>WJ01024</intervention_name>
    <description>80mg: WJ01024, Q4W, twice per week</description>
    <arm_group_label>WJ01024 80mg repeat dose every 28 days</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>WJ01024</intervention_name>
    <description>100mg: WJ01024, Q4W, twice per week</description>
    <arm_group_label>WJ01024 100mg repeat dose every 28 days</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>WJ01024</intervention_name>
    <description>120mg: WJ01024, Q4W, twice per week</description>
    <arm_group_label>WJ01024 120mg repeat dose every 28 days</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>WJ01024</intervention_name>
    <description>140mg: WJ01024, Q4W, twice per week</description>
    <arm_group_label>WJ01024 140mg repeat dose every 28 days</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>WJ01024</intervention_name>
    <description>1600mg: WJ01024, Q4W, twice per week</description>
    <arm_group_label>WJ01024 160mg repeat dose every 28 days</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        &quot;Inclusion criteriaï¼š&#xD;
&#xD;
          1. Patients with advanced malignant neoplasms definitively diagnosed by pathology and/or&#xD;
             cytology who have failed to respond to conventional treatment or are lacking effective&#xD;
             treatment;&#xD;
&#xD;
          2. For patients with solid tumors, there should be evaluable or measurable tumor lesions&#xD;
             according to RECIST 1.1 criteria (not for dose-climbing phase);&#xD;
&#xD;
          3. Males and females â‰¥ 18 and â‰¤ 70 years of age,ECOG performance status of 0~1;&#xD;
&#xD;
          4. Life expectancy â‰¥3 months;&#xD;
&#xD;
          5. The functions of the major organs were basically normal, and the following laboratory&#xD;
             tests were performed within 7 days before the first administration of the study drug&#xD;
             (no blood transfusion or colony-stimulating factor was administered within 14 days&#xD;
             before the examination);&#xD;
&#xD;
          6. For premenopausal women who are likely to have children, a pregnancy test must be&#xD;
             performed within 7 days before the first use of the study drug. The blood pregnancy&#xD;
             test must be negative and must be non-lactating.All enrolled patients (both male and&#xD;
             female) should take adequate barrier contraception throughout the treatment period and&#xD;
             3 months after the end of treatment;&#xD;
&#xD;
          7. Voluntary participant in this drug clinical trial, able to understand and sign the&#xD;
             informed consent.&#xD;
&#xD;
        Exclusion criteria&#xD;
&#xD;
          1. Pregnant or lactating women;&#xD;
&#xD;
          2. Suffer from other serious complications (such as uncontrolled infection, myocardial&#xD;
             infarction within 6 months, uncontrolled hypertension and thromboembolic disease);&#xD;
&#xD;
          3. There was active graft rejection at the time of enrollment (after allogeneic stem cell&#xD;
             transplantation);&#xD;
&#xD;
          4. Who is not suitable for the study after laboratory examination (blood routine, urine&#xD;
             routine, blood biochemical, blood coagulation function) or as judged by the study&#xD;
             physician;&#xD;
&#xD;
          5. â‰¥ Grade 2 toxicity after previous treatment;&#xD;
&#xD;
          6. Patients with grade 2 or more neuropathy;&#xD;
&#xD;
          7. A person suffering from an uncontrollable mental illness;&#xD;
&#xD;
          8. Have a history of drug abuse or urine drug screening positive;&#xD;
&#xD;
          9. Heart disease: New York heart association (NYHA) &gt; class II congestive heart failure,&#xD;
             unstable angina (resting angina symptoms), new angina (within 6 months before entering&#xD;
             the study), into the group of the first six months of myocardial infarction, or need&#xD;
             anti-arrhythmic treatment for arrhythmia (allows the use of beta blockers, calcium&#xD;
             channel blockers and digoxin);&#xD;
&#xD;
         10. Alcoholics or those who consume more than 28 units of alcohol per week (1 unit = 285&#xD;
             mL beer or 25 mL spirits (40%v/v) or 1 glass [100ml] of wine);&#xD;
&#xD;
         11. Patients with active hepatitis B, hepatitis C, HIV (+) and syphilis antibody&#xD;
             (+);Patients with HBsAg or core antibody (HBcAb) positivity need to be tested for&#xD;
             HBV-DNA, and HBV-DNA is lower than the upper limit of normal to be enrolled.Patients&#xD;
             with hepatitis C virus antibody (HCV Ab) positive should be tested for HCV RNA, and&#xD;
             those below the upper limit of normal can be enrolled.&#xD;
&#xD;
         12. Requiring long-term corticosteroids or other immunosuppressive therapy, such as those&#xD;
             who have had organ transplants;&#xD;
&#xD;
         13. Other conditions considered ineligible by the investigator.&quot;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jun Ma, Doctor</last_name>
    <phone>0451-84883437</phone>
    <email>mjun@csco.org.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jun Zhu, Doctor</last_name>
    <phone>010-88196115</phone>
    <email>zhujun3346@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Harbin The First Hospitall</name>
      <address>
        <city>Harbin</city>
        <state>Heilongjiang</state>
        <zip>150010</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jun Ma, MD</last_name>
      <phone>0451-84883437</phone>
      <email>mjun@csco.org.cn</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jilin Cancer Hospital</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <zip>130012</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ying Cheng, MD</last_name>
      <phone>0431-80596067</phone>
      <email>jl.cheng@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beijing Cancer Hospital</name>
      <address>
        <city>Beijing</city>
        <state>åŒ—äº¬å¸‚</state>
        <zip>100142</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jun Zhu</last_name>
      <phone>010-88196115</phone>
      <email>zhujun3346@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 14, 2021</study_first_submitted>
  <study_first_submitted_qc>August 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 5, 2021</study_first_posted>
  <last_update_submitted>November 3, 2021</last_update_submitted>
  <last_update_submitted_qc>November 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hematologic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

